Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
On the basis of a coverage decision for anti-amyloid monoclonal antibodies recently issued by the US Centers for Medicare and Medicaid Services, Medicare will offer ‘coverage with evidence development’ to allow more information on the clinical benefits of these antibodies to be gathered. Here, we discuss the implications of this decision for future clinical trials and Alzheimer disease care.
New research shows that meningeal lymphatic vessels can drain viruses from the CNS, with important implications for our understanding of CNS infections.
A new study provides evidence that inflammation protects against the development of chronic pain in people with acute back pain, and that anti-inflammatory drugs used to treat acute pain could do more harm than good in the long term.
A recent publication reveals progressive, dose-dependent ventricular enlargement in the brains of patients with early Alzheimer disease who were treated with the FDA-approved drug aducanumab. Aducanumab joins a growing list of anti-amyloid-β therapies for which there is evidence that they cause accelerated neurodegeneration; extended follow-up studies are required to determine whether aducanumab causes progressive brain damage.
A new paper published in Neuron presents an analysis of mRNA expression in human and mouse trigeminal ganglia at single-nucleus resolution. The resulting resource is thought-provoking and suggests new targets for pain therapies; however, the findings should be interpreted in the context of the available protein data and warrant functional verification.
A new genome-wide association study has identified 41 previously unknown loci associated with Alzheimer disease. However, these data provide limited insight into disease mechanisms or benefits for clinical prediction of Alzheimer disease.
Consensus is growing that intervention in the very early stages of Alzheimer disease is necessary for disease modification. Here, the authors discuss the challenges of recruiting asymptomatic or mildly symptomatic participants for clinical trials, focusing on ‘trial-ready’ cohorts as a potential solution.
Recent technological advances have enabled the detection of specific forms of phosphorylated tau in blood. Here, the authors summarize the performance of blood phosphorylated tau biomarkers in the context of Alzheimer disease and highlight related ethical, analytical and clinical challenges.
In this Perspectives article, David Fischer and colleagues present a stepwise conceptual framework for neuroprognostication after severe brain injury, with the aim of providing structure and guidance to supplement clinical judgement and direct future investigation.
Many episodes of status epilepticus do not respond to first-line treatment with benzodiazepines. In this Perspective, Richard Burman and colleagues discuss seizure-induced alterations to the sensitivity of the GABA receptor to benzodiazepines, presenting these changes as a possible mechanism of treatment resistance.
